Created in 2010, RoundTable’s pharmaceutical business, the Topical Division of Renaissance Acquisition Holdings, develops, sells and markets generic topical pharmaceutical products. Renaissance acts as a pipeline for some two dozen abbreviated new drug applications and new drug applications, and is one of the largest private manufacturers in the U.S. dermatology market.
The transaction will allow Renaissance to continue to own and operate its specialty pharmaceutical business located in Lakewood, N.J.
“This transaction marks the first portfolio company sale from RoundTable’s $600 million Fund III, generating a return of more than five times invested equity capital for our investors,” RoundTable Founding Partner Lester B. Knight said.
More articles on healthcare transactions and valuations:
FTC gains 3 “friends of the court” briefs filed in favor of blocking Hershey-PinnacleHealth merger
Kern Medical Center transferred to new hospital authority
Ontario Systems takes over Ultimate Business Systems: 5 things to know
